Scott Davies Biography and Net Worth

Chief Legal Officer of Illumina

As Chief Legal Officer, Scott Davies has worldwide responsibility for all legal and intellectual property matters, regulatory, government affairs, and market access. He also serves as Illumina's code of ethics compliance officer.

Prior to his appointment, Davies served as Illumina’s interim General Counsel and Secretary, and prior to that, Illumina’s Vice President, Legal – Chief Corporate Counsel and Assistant Secretary. Davies joined Illumina in 2009 as its first corporate-focused attorney and has managed all of Illumina’s significant corporate legal matters and transactions since that time. While taking on positions of increasing responsibility, Davies developed and led a global corporate and commercial legal team and has worked closely with Illumina’s senior executive team and board of directors on a wide range of legal matters across the spectrum of Illumina’s global business operations.

Prior to joining Illumina, Davies was a corporate transactions (M&A), securities, and finance attorney for 12 years, including 10 years with Gibson, Dunn & Crutcher LLP, a leading international law firm, and two years with Allen & Overy, a leading UK-based global law firm, resident in its London office.

Davies received a J.D. from Cornell Law School and a B.A. from Brigham Young University.

What is Scott M. Davies' net worth?: The estimated net worth of Scott M. Davies is at least $2.35 million as of December 12th, 2025. Mr. Davies owns 17,887 shares of Illumina stock worth more than $2,353,214 as of December 17th. This net worth evaluation does not reflect any other investments that Mr. Davies may own. Learn More about Scott M. Davies' net worth.
How do I contact Scott M. Davies?: The corporate mailing address for Mr. Davies and other Illumina executives is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. Illumina can also be reached via phone at (858) 202-4500 and via email at [email protected]. Learn More on Scott M. Davies' contact information.
Has Scott M. Davies been buying or selling shares of Illumina?: During the past quarter, Scott M. Davies has sold $43,957.07 in Illumina stock. Most recently, Scott M. Davies sold 323 shares of the business's stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a transaction totalling $43,957.07. Following the completion of the sale, the insider now directly owns 17,887 shares of the company's stock, valued at $2,434,241.83. Learn More on Scott M. Davies' trading history.
Who are Illumina's active insiders?: Illumina's insider roster includes Alexander Aravanis (SVP), Frances Arnold (Director), Charles Dadswell (SVP), Scott Davies (Chief Legal Officer), Francis deSouza (CEO), Phillip Febbo (SVP), Jay Flatley (Director), Scott Gottlieb (Director), Aimee Hoyt (SVP), Karen Mcginnis (CAO), Robert Ragusa (SVP), Mostafa Ronaghi (SVP), Sam Samad (CFO), Jacob Thaysen (CEO), Susan Tousi (SVP), and Mark Van Oene (SVP). Learn More on Illumina's active insiders.
Are insiders buying or selling shares of Illumina?: In the last year, Illumina insiders bought shares 2 times. They purchased a total of 6,600 shares worth more than $556,446.00. In the last year, insiders at the life sciences company sold shares 1 times. They sold a total of 323 shares worth more than $43,957.07. The most recent insider tranaction occured on December, 12th when insider Scott M Davies sold 323 shares worth more than $43,957.07. Insiders at Illumina own 0.2% of the company. Learn More about insider trades at Illumina.
Information on this page was last updated on 12/12/2025.

Scott M. Davies Insider Trading History at Illumina

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/12/2025	Sell	323	$136.09	$43,957.07	17,887

Scott M. Davies Buying and Selling Activity at Illumina

Illumina Company Overview

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Today's Range

Now: $129.88

$129.29

$133.90

50 Day Range

MA: $116.09

$91.00

$136.44

2 Week Range

Now: $129.88

$68.70

$153.06

Volume

559,905 shs

Average Volume

2,119,722 shs

Market Capitalization

$19.85 billion

P/E Ratio

29.06

Dividend Yield

N/A

Beta

1.44